OncoSil Medical's (ASX:OSL) managing director Daniel Kenny talks pathway to CE Mark approval with Proactive Investors.
VIEW FULL INTERVIEW HERE
OncoSil's lead product candidate is the OncoSil™ medical device, which is focussed on localised radiation treatment for cancer.OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment.
The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation.
News: OncoSil Medical's Daniel Kenny talks path to CE Mark with Proactive Investors
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.070(5.69%) |
Mkt cap ! $16.49M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.25 | $1.11 | $72.36K | 60.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9286 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 412 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |